Analysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $36.00

Shares of Xencor, Inc. (NASDAQ:XNCR) have earned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $36.00.

Several analysts recently issued reports on XNCR shares. Royal Bank of Canada reissued an “outperform” rating and set a $32.00 target price on shares of Xencor in a research note on Wednesday, February 28th. BTIG Research lowered their target price on shares of Xencor from $56.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, April 16th. StockNews.com upgraded shares of Xencor from a “sell” rating to a “hold” rating in a report on Saturday, March 9th. Piper Sandler restated a “neutral” rating and set a $24.00 price objective (down previously from $37.00) on shares of Xencor in a research report on Wednesday, February 28th. Finally, BMO Capital Markets cut their price target on Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th.

Xencor Stock Performance

Shares of XNCR stock opened at $24.31 on Friday. The firm has a market capitalization of $1.50 billion, a PE ratio of -11.58 and a beta of 0.77. The company has a 50 day moving average price of $21.85 and a 200-day moving average price of $20.54. Xencor has a 52 week low of $16.49 and a 52 week high of $28.96. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 0.02.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of $0.36 by ($0.67). The business had revenue of $44.70 million for the quarter, compared to analysts’ expectations of $77.63 million. Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. Xencor’s revenue for the quarter was up 106.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.20) EPS. As a group, equities research analysts expect that Xencor will post -3.25 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP John R. Desjarlais sold 54,108 shares of the stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total value of $1,048,613.04. Following the sale, the vice president now owns 161,675 shares of the company’s stock, valued at $3,133,261.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Kurt A. Gustafson sold 14,000 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $23.18, for a total transaction of $324,520.00. Following the completion of the transaction, the director now owns 6,007 shares in the company, valued at approximately $139,242.26. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP John R. Desjarlais sold 54,108 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the completion of the sale, the vice president now owns 161,675 shares in the company, valued at approximately $3,133,261.50. The disclosure for this sale can be found here. Insiders sold 101,351 shares of company stock valued at $2,152,417 over the last three months. 5.23% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC boosted its position in Xencor by 303.9% in the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,015 shares during the period. CWM LLC boosted its holdings in shares of Xencor by 498.7% in the fourth quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,147 shares during the period. Signaturefd LLC grew its stake in Xencor by 367.7% in the fourth quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,151 shares in the last quarter. BluePath Capital Management LLC bought a new position in Xencor in the third quarter worth approximately $31,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Xencor by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 756 shares during the period.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.